Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Duygu Saatcioglu"'
Autor:
Hatice Duygu Saatcioglu, Motohiro Kano, Heiko Horn, Lihua Zhang, Wesley Samore, Nicholas Nagykery, Marie-Charlotte Meinsohn, Minsuk Hyun, Rana Suliman, Joy Poulo, Jennifer Hsu, Caitlin Sacha, Dan Wang, Guangping Gao, Kasper Lage, Esther Oliva, Mary E Morris Sabatini, Patricia K Donahoe, David Pépin
Publikováno v:
eLife, Vol 8 (2019)
The Mullerian ducts are the anlagen of the female reproductive tract, which regress in the male fetus in response to MIS. This process is driven by subluminal mesenchymal cells expressing Misr2, which trigger the regression of the adjacent Mullerian
Externí odkaz:
https://doaj.org/article/dc7ad2dba29a41beb65fb95ef1219743
Autor:
H Duygu Saatcioglu, Juan Valle, Teresa Macarulla, Milind Javle, Do-Youn Oh, Lipika Goyal, Jake Conway, Janani Iyer, Fedaa Najdawi, Chintan Shah, Camelia Gliser, Susan Pandya, Scott Daigle, Ghassan Abou-Alfa, Robin Kelley
Publikováno v:
Regular and Young Investigator Award Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f704e0a64f9f98518cd5f909c0b3d418
https://doi.org/10.1136/jitc-2022-sitc2022.0552
https://doi.org/10.1136/jitc-2022-sitc2022.0552
Publikováno v:
PLoS Genetics, Vol 12, Iss 8, p e1006215 (2016)
In mammals, females are born with finite numbers of oocytes stockpiled as primordial follicles. Oocytes are "reawakened" via an ovarian-intrinsic process that initiates their growth. The forkhead transcription factor Foxo3 controls reawakening downst
Externí odkaz:
https://doaj.org/article/e6a918fe0a614e4297645e4bf27d821b
Autor:
Martin S. Tallman, Salah Nabhan, Michael R. Savona, Bob Löwenberg, Hartmut Döhner, Courtney D. DiNardo, Eric S. Winer, Eytan M. Stein, James K. McCloskey, Olatoyosi Odenike, Vickie Zhang, Frederik Lersch, Amir T. Fathi, Richard Stone, Daniel A. Pollyea, Michael R. Cooper, Anthony S. Stein, Mikhail Roshal, Alice S. Mims, Gert J. Ossenkoppele, Duygu Saatcioglu, Prapti A. Patel, Caroline Almon, Mark G. Frattini, Hagop M. Kantarjian, Christopher S. Seet
Publikováno v:
Blood. 138:1276-1276
Background: Ivosidenib (IVO) and enasidenib (ENA) are oral inhibitors of mutant IDH1 (mIDH1) and mutant IDH2 (mIDH2), respectively, FDA-approved for the treatment of relapsed/refractory IDH-mutant acute myeloid leukemia (AML). Here we report updated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::24870e3b2bd489f6f098a983c5e7abfa
https://doi.org/10.1182/blood-2021-146507
https://doi.org/10.1182/blood-2021-146507